☆ 4.3 Editorial Material

Bempegaldesleukin (NKTR-214): a CD-122-biased IL-2 receptor agonist for cancer immunotherapy

EXPERT OPINION ON BIOLOGICAL THERAPY (2019)

Get Full Text
Add to Collection

Journal

EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 19, Issue 12, Pages 1223-1228

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2019.1685489

Keywords

Bempegaldesleukin; checkpoint inhibitors; interleukin-2 (IL-2); PD-1/PD-L1 inhibitors; CD122-preferential IL-2 receptor agonist

Categories

Biotechnology & Applied Microbiology Medicine, Research & Experimental

Funding

  1. Nektar Therapeutics

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.